BVAXF (BioVaxys Technology) Scaled Net Operating Assets : -0.37 (As of Jul. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

BioVaxys Technology's operating assets for the quarter that ended in Jul. 2024 was $1.40 Mil. BioVaxys Technology's operating liabilities for the quarter that ended in Jul. 2024 was $1.88 Mil. BioVaxys Technology's Total Assets for the quarter that ended in Apr. 2024 was $1.29 Mil. Therefore, BioVaxys Technology's scaled net operating assets (SNOA) for the quarter that ended in Jul. 2024 was -0.37.

BioVaxys Technology Scaled Net Operating Assets Historical Data

The historical data trend for BioVaxys Technology's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Scaled Net Operating Assets Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Scaled Net Operating Assets

Get a 7-Day Free Trial

-0.36

23.27

0.77

-0.10

-3.89

BioVaxys Technology Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Scaled Net Operating Assets	Get a 7-Day Free Trial															-0.24	-2.30	-20.57	-0.74	-0.37

Competitive Comparison of BioVaxys Technology's Scaled Net Operating Assets

For the Biotechnology subindustry, BioVaxys Technology's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVaxys Technology's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVaxys Technology's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where BioVaxys Technology's Scaled Net Operating Assets falls into.

BioVaxys Technology Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

BioVaxys Technology's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Oct. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Oct. 2023 )
=	(Operating Assets (A: Oct. 2023 )	-	Operating Liabilities (A: Oct. 2023 ))	/	Total Assets (A: Oct. 2022 )
=	(0.081	-	2.542)	/	0.633
=	-3.89

where

	Operating Assets		(A: Oct. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	0.082	-	0.001
=	0.081

	Operating Liabilities		(A: Oct. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	2.542	-	0	-	0
=	2.542

BioVaxys Technology's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jul. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Jul. 2024 )
=	(Operating Assets (Q: Jul. 2024 )	-	Operating Liabilities (Q: Jul. 2024 ))	/	Total Assets (Q: Apr. 2024 )
=	(1.398	-	1.878)	/	1.292
=	-0.37

where

	Operating Assets		(Q: Jul. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	1.756	-	0.358
=	1.398

	Operating Liabilities		(Q: Jul. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	1.937	-	0	-	0.059
=	1.878

BioVaxys Technology Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

5LB:Germany BIOV:Canada

Address

146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.